FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2885496181> ?p ?o ?g. }

• W2885496181 endingPage "1948" @default.
• W2885496181 startingPage "1940" @default.
• W2885496181 abstract "IntroductionThymoma and thymic carcinoma (TC) are neoplastic diseases with reported chemosensitivity to a broad range of agents. However, because of the rarity of these diseases, few prospective trials have been conducted in patients with advanced thymic malignancies. We conducted a prospective phase II trial to evaluate the clinical activity of pemetrexed, a multitargeted antifolate agent, in previously treated patients with thymoma and TC.MethodsA total of 27 previously treated patients (16 with thymoma and 11 with TC) with advanced, unresectable disease were treated with pemetrexed, 500 mg/m2, intravenously every 3 weeks for a maximum of six cycles or until undue toxicity or progressive disease. All patients received folic acid, vitamin B12, and steroid prophylaxis.ResultsThe median number of cycles administered was 6 (range 1–6). Nine patients with a total of 14 events had grade 3 toxicities; no grade 4 toxicities were noted. In 26 fully evaluable patients, two complete and three partial responses (according to the Response Evaluation Criteria in Solid Tumors) were documented (all in patients with stage IVA thymoma, except for one partial response with stage IVA TC). A total of 14 patients completed the full six cycles of treatment, 7 patients progressed while undergoing therapy, 5 patients discontinued therapy because of intolerance, and 1 patient discontinued therapy because of progressive Morvan syndrome. The median progression-free survival time for all patients was 10.6 months (12.1 months for those with thymoma versus 2.9 months for those with TC). With 23 deaths at data cutoff, the median overall survival time was 28.7 months (46.4 months for those with thymoma versus 9.8 months for those with TC).ConclusionsPemetrexed is an active agent in this heavily pretreated population of patients with recurrent thymic malignancies, especially thymoma." @default.
• W2885496181 created "2018-08-22" @default.
• W2885496181 creator A5021904320 @default.
• W2885496181 creator A5024771370 @default.
• W2885496181 creator A5027378158 @default.
• W2885496181 creator A5039459816 @default.
• W2885496181 creator A5051654669 @default.
• W2885496181 creator A5059878540 @default.
• W2885496181 creator A5085319465 @default.
• W2885496181 date "2018-12-01" @default.
• W2885496181 modified "2023-10-15" @default.
• W2885496181 title "A Phase II Study of Pemetrexed in Patients with Recurrent Thymoma and Thymic Carcinoma" @default.
• W2885496181 cites W1955256716 @default.
• W2885496181 cites W1980451287 @default.
• W2885496181 cites W1985329793 @default.
• W2885496181 cites W1992415548 @default.
• W2885496181 cites W2022950401 @default.
• W2885496181 cites W2028094629 @default.
• W2885496181 cites W2029621550 @default.
• W2885496181 cites W2029727269 @default.
• W2885496181 cites W2054507362 @default.
• W2885496181 cites W2056129513 @default.
• W2885496181 cites W2056959009 @default.
• W2885496181 cites W2064684469 @default.
• W2885496181 cites W2067629373 @default.
• W2885496181 cites W2079938100 @default.
• W2885496181 cites W2080181833 @default.
• W2885496181 cites W2090211721 @default.
• W2885496181 cites W2092536220 @default.
• W2885496181 cites W2102627969 @default.
• W2885496181 cites W2127235139 @default.
• W2885496181 cites W2128986224 @default.
• W2885496181 cites W2130099089 @default.
• W2885496181 cites W2134667653 @default.
• W2885496181 cites W2139248078 @default.
• W2885496181 cites W2139863684 @default.
• W2885496181 cites W2139939379 @default.
• W2885496181 cites W2143289575 @default.
• W2885496181 cites W2148716917 @default.
• W2885496181 cites W2153426514 @default.
• W2885496181 cites W2167601464 @default.
• W2885496181 cites W2168071502 @default.
• W2885496181 cites W2168558240 @default.
• W2885496181 cites W2321791130 @default.
• W2885496181 cites W2344626604 @default.
• W2885496181 cites W2415082602 @default.
• W2885496181 cites W2529312611 @default.
• W2885496181 cites W2552029697 @default.
• W2885496181 cites W2606601794 @default.
• W2885496181 cites W2613990243 @default.
• W2885496181 cites W2786718111 @default.
• W2885496181 cites W2938214910 @default.
• W2885496181 doi "https://doi.org/10.1016/j.jtho.2018.07.094" @default.
• W2885496181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30121390" @default.
• W2885496181 hasPublicationYear "2018" @default.
• W2885496181 type Work @default.
• W2885496181 sameAs 2885496181 @default.
• W2885496181 citedByCount "34" @default.
• W2885496181 countsByYear W28854961812019 @default.
• W2885496181 countsByYear W28854961812020 @default.
• W2885496181 countsByYear W28854961812021 @default.
• W2885496181 countsByYear W28854961812022 @default.
• W2885496181 countsByYear W28854961812023 @default.
• W2885496181 crossrefType "journal-article" @default.
• W2885496181 hasAuthorship W2885496181A5021904320 @default.
• W2885496181 hasAuthorship W2885496181A5024771370 @default.
• W2885496181 hasAuthorship W2885496181A5027378158 @default.
• W2885496181 hasAuthorship W2885496181A5039459816 @default.
• W2885496181 hasAuthorship W2885496181A5051654669 @default.
• W2885496181 hasAuthorship W2885496181A5059878540 @default.
• W2885496181 hasAuthorship W2885496181A5085319465 @default.
• W2885496181 hasBestOaLocation W28854961811 @default.
• W2885496181 hasConcept C126322002 @default.
• W2885496181 hasConcept C141071460 @default.
• W2885496181 hasConcept C143998085 @default.
• W2885496181 hasConcept C146357865 @default.
• W2885496181 hasConcept C151730666 @default.
• W2885496181 hasConcept C188816634 @default.
• W2885496181 hasConcept C2776349617 @default.
• W2885496181 hasConcept C2776694085 @default.
• W2885496181 hasConcept C2777240266 @default.
• W2885496181 hasConcept C2778239845 @default.
• W2885496181 hasConcept C2778822529 @default.
• W2885496181 hasConcept C2779159893 @default.
• W2885496181 hasConcept C31760486 @default.
• W2885496181 hasConcept C71924100 @default.
• W2885496181 hasConcept C86803240 @default.
• W2885496181 hasConcept C90924648 @default.
• W2885496181 hasConceptScore W2885496181C126322002 @default.
• W2885496181 hasConceptScore W2885496181C141071460 @default.
• W2885496181 hasConceptScore W2885496181C143998085 @default.
• W2885496181 hasConceptScore W2885496181C146357865 @default.
• W2885496181 hasConceptScore W2885496181C151730666 @default.
• W2885496181 hasConceptScore W2885496181C188816634 @default.
• W2885496181 hasConceptScore W2885496181C2776349617 @default.
• W2885496181 hasConceptScore W2885496181C2776694085 @default.
• W2885496181 hasConceptScore W2885496181C2777240266 @default.
• W2885496181 hasConceptScore W2885496181C2778239845 @default.

• next